Kornimate/medical-research-clean huggingface dataset:
intravenous lidocaine for treating intrathecal fentanyl induced pruritus

Conditions: Pruritus Caused by Drug

Summary: the study will assess efficacy of intravenous lidocaine 1 mg/kg diluted with 0.9% sodium chloride to a volume of 100 ml to suppress intrathecal fentanyl induced pruritus. this will be compared to control group who will receive 100 ml normal saline as placebo. the main outcome is regression of initial vas score with incidence of pruritus.

the study will include adult patients who are admitted for orthopedic operations and urosurgery who are planned to receive spinal anesthesia. the study will include adult patients aging from 18 to 70 years old. asa i to iii. the study will exclude the patients who receive antihistamine drugs, patients who suffer any type of coagulopathy, patients who are suffering any type of pruritus before receiving spinal anesthesia and patients who are known allergic to lidocaine. all the patients will receive 500 ml ringer lactate as a volume preload. the patients will be monitored by spo2, noninvasive blood pressure and ecg. the spinal anesthesia drugs will be hyperbaric bupivacaine (the dose will be adjusted according to the required level of anesthesia) and 25 mic of fentanyl as an additive. the subjects of the study will not receive any type of sedation. if any patient suffered bradycardia associated with hypotension which necessitate management by atropine or ephedrine, he will be excluded from the study. before the surgery, patients could cooperate and understand the visual analogue score (vas) scale. patients will be explained about the use of vas for grading the severity of pruritus on a scale of 0 to 10. vas = 0 means no pain or itching, vas = 10 means worst sensation and vas \> 4 means it need intervention. the affected areas by itching will be asked. the study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. the vas will be assessed every 10 minutes for 60minutes after the treatment. a regression of more than 4 points of vas score is considered a success and if less than 4 points , it will be considered as a failure. the control group will receive 100 ml of normal saline as placebo effect and vas will be assessed in same manner as the study group.

Eligibility criteria:
inclusion criteria: * patients who are admitted for orthopedic operations and urosurgery who are planned to receive spinal anesthesia. * the study will include adult patients aging from 18 to 70 years old. asa i to iii. exclusion criteria: * the patients who receive antihistamine drugs * patients who suffer any type of coagulopathy * patients who are suffering any type of pruritus before receiving spinal anesthesia * patients who are known allergic to lidocaine.

Keywords: spinal anesthesia pruritus lidocaine
embryogen/ blastgen for couples with implantation problems or previous miscarriage

Conditions: Recurrent Miscarriage; Infertility

Summary: embryogen and blastgen contain the cytokine growth factor granulocyte-macrophage colony-stimulating factor (gm-csf), which has been documented to give significant benefit to this difficult group of patients. results showed a highly significant effect of 44% relative improvement in ongoing implantation rate (p=0.001) in women who have previously miscarried (ziebe et al 2013). we wish to undertake a randomised controlled trial to determine if embryogen/blastgen media improves pregnancy outcomes in women with recurrent implantation failure, recurrent miscarriage and poor embryo development when compared to standard media.

a randomised control pilot study will be undertaken for 100 women who have implantation failure (≥ 2 embryo transfers without a pregnancy) or at least 1 previous miscarriage and are having a further ivf cycle. at oocyte retrieval each couple will be randomised using numbered envelopes containing pre randomised group allocations by a person uninvolved in the trial to: 1. blastgen group (n=50): culturing their embryos in origio standard, sequential culture mediums for 3 days (embryogen included) then blastgen media (gm-csf containing media) for remaining 2 days or 2. standard media group (n=50): culturing their embryos in cook standard sequential medium for 5 days. the best single embryo will be transferred on day 5. the clinical staff and participating couple will be blinded as to whether blastgen or standard media was used in culture to day 5. fertility sa embryologists will not be blind as to which study group a couple is in and which media is being used. the embryos will be cultured using the usual methods and lab facilities by fertility sa's current embryology staff members who will not be blind to the media being used. records on the outcome of the oocyte fertilisation, blastocyst development, implantation rate and pregnancy rates will be recorded, as is standard practice. pregnancy scans will be carried out at 7 and 12 weeks. live birth outcomes and any congenital anomalies will be recorded.

Eligibility criteria:
inclusion criteria: * women undertaking an ivf or icsi cycle * aged between 25 and 41 years * 2 or more embryos transferred without a positive pregnancy outcome or a history of at least 1 previous pregnancy loss, or * poor embryo development (\<20% of embryo developing on time at day 3 or no blastocyst above grade 2 on day 5) exclusion criteria: * male partner requiring surgical retrieval of sperm except in cases of previous vasectomy * the use of another investigational drug within 30 days * any severe chronic disease that would significantly influence an ivf cycle * less than 3 follicles\>14mm on ultrasound on the day of hcg trigger
active navigation training

Conditions: Mild Cognitive Impairment; Spatial Navigation

Summary: pilot testing and development of an immersive virtual reality system for spatial navigation training in mild cognitive impairment syndrome.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild cognitive impairment * absence of severe cognitive deterioration as assessed by the italian version of the mmse (magni et al. 1996) * age ≥ 60 exclusion criteria: * the presence of acute stroke/transient ischemic attack; * the presence of other concomitants severe neurological/psychiatric diseases; * history of traumatic brain injury with loss of consciousness; * physical/functional deficits that could affect the use of immersive virtual reality; * severe visual deficiency; * the presence of recurrent vertigo.

Keywords: virtual reality
effects of respiratory muscle functions on interstitial lung disease: sleep quality, dyspnea, and fatigue

Conditions: Interstitial Lung Disease

Summary: although there are numerous data demonstrating the impact of interstitial lung disease (ild) on respiratory functions, there is a lack of studies investigating the effects of respiratory functions on parameters such as sleep quality, dyspnea, and fatigue. the primary objective of the study is to examine the influence of changes in respiratory muscle functions in ild on sleep quality, dyspnea, and fatigue parameters. the secondary objective is to investigate the effects of respiratory muscle functions in ild on parameters such as cough, pain, exercise capacity, peripheral muscle strength, anxiety, depression, and quality of life.

introduction: despite having numerous data demonstrating the impact of interstitial airway disease (iad) on respiratory functions, there is a lack of studies investigating the effects of respiratory functions on parameters such as sleep quality, dyspnea, and fatigue. the primary objective of the study is to examine the effects of changes in respiratory muscle functions in iad on sleep quality, dyspnea, and fatigue parameters. the secondary objective is to investigate the effects of respiratory muscle functions in iad on parameters such as cough, pain, exercise capacity, peripheral muscle strength, anxiety, depression, and quality of life. methods: between june 2020 and june 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the department of chest diseases at istanbul university, istanbul faculty of medicine, and met the inclusion criteria, were included in the project. participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated. pearson correlation test was applied to determine the relationship between variables. multiple linear regression analysis was used to examine factors that could affect respiratory muscle strength and endurance values.

Eligibility criteria:
inclusion criteria: * being 18 years of age or older. * having a diagnosis of interstitial lung disease (ild) by a chest diseases specialist. exclusion criteria: * systemic involvement of ild * cooperation problem * presence of orthopedic/neurological issues hindering walking and exercise. * uncontrolled cardiovascular disease. * presence of acute upper and lower respiratory tract infections.

Keywords: interstitial lung disease respiratory muscles sleep quality of life fatigue
an observational registry using drug eluting stents (des) in patients in a real-world setting (descover registry).

Conditions: Cardiovascular Diseases; Vascular Disease; Arterial Occlusive Disease; Arteriosclerosis; Atherosclerosis

Summary: the descover registry is designed to observe the results of using drug eluting stents (des) in patients in a real-world setting. the stents being observed are not investigational, that is, they have been approved for use in the general population.

the d.e.s.cover registry is a prospective, multi-center, observational study. consecutive patients undergoing pci procedures will be asked to consent to participate in this study. for these patients, baseline, clinical and angiographic characteristics, as well as certain procedural and clinical events will be recorded using standardized case report forms. outcomes will be assessed during hospitalization and at one, six and twelve months after discharge. depending on results from the first year of follow-up, the study may be extended with an additional one or two years of follow-up. the strategy for achieving the scientific objectives of the registry is to document actual, real-world pci practice and outcomes. accordingly, the d.e.s.cover registry does not specify treatment protocols, require any particular assignment of patients to treatment protocols, or in any other way require participating physicians to alter their practice patterns. participating physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the d.e.s.cover registry database.

Eligibility criteria:
inclusion criteria: * consecutive patients undergoing percutaneous coronary intervention at an enrolling center by study investigators exclusion criteria: * patient refusal or inability to provide written informed consent and/or hipaa authorization

Keywords: coronary disease arteries atherosclerosis arteriosclerosis
impact of anaesthesiology management on paediatric emergence delirium incidence

Conditions: Emergence Delirium

Summary: postoperative emergence delirium (ed) is a severe postoperative complication in paediatric anaesthesia. ed is defined as a state with psychomotor disturbance, perception disorder and state of excitation and anxiety. the incidence of ed in paediatric patients can be up to 80%. ed is associated with the increased morbidity of paediatric patients in the postoperative period. one of the potential triggers of ed is sevoflurane. currently, there are only limited data about comparing the influence of anesthesiologic management on the ed incidence. the possible ed reduction could lead to reduced stay in a post-anaesthesia care unit (pacu), postoperative nausea and vomiting (ponv) incidence and the overall reduction of the postoperative adverse events incidence together with the higher satisfaction and the patients and the legal guardians.

this prospective randomized interventional single-blind study aims to compare the influence of the anaesthesiology management no the incidence of ed in the postoperative period in paediatric patients. elective paediatric patients (2-10 years) scheduled for the planned adenoidectomy or adenoidectomy + micro-otoscopy/adenoidectomy + frenulum linguae discission will be included in the trial after signed informed consent form the legal guardian. in all patients, the 2 eutectic mixture of local anesthetics (emla) patch will be applied on the predefined skin area ( visible vein for venepuncture) between 45 minutes to 60 minutes before anaesthesia. the patients will be randomized at the operating theatre (allocation 1:1) into the experimental group (intravenous induction with propofol + opioid and anaesthesia maintenance according to this set bispectral index value with desflurane) and the control group (inhalation induction with sevoflurane mixed with air and oxygen and anaesthesia maintenance with sevoflurane). the primary aim of the study will be the incidence of ed defined by the pediatric anesthesia emergence delirium (paed) scale, which will be measured at the , at the admission to pacu and in the 5th, 10th, 15th, 30th minute and at the moment of dismission from pacu. the secondary aim will be the time to oral intake (from the end of the surgery), the incidence of adverse events (ponv, bradycardia, hypotension), the need for concomitant medication (analgesic medication, sedative medication, antiemetic medication).

Eligibility criteria:
inclusion criteria: * age between 2-10 years * signed informed consent * paediatric patient for elective adenoidectomy, or adenoidectomy with micro-otoscopy and/or frenulum discission exclusion criteria: * allergy and hypersensitivity on local anaesthetics in emla patch, general anaesthetics, or soya beans or peanuts * venepuncture refusal · neuromuscular disorder with the contraindication of inhalation anaesthetics

Keywords: delirium emergence delirium paediatric patient anaesthesia
amyotrophic lateral sclerosis (als) families project

Conditions: ALS

Summary: this program provides family members of individuals with familial als the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. this study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. this study will follow unaffected als gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of als.

approximately 10% of people with amyotrophic lateral sclerosis (als), or lou gehrig's disease, have a family history of als or a related condition called frontotemporal dementia (ftd). in most of these familial cases, and a significant number of "sporadic" patients with no family history, a mutation is present in one of a growing number of genes that have been associated with als and/or ftd. the als families project will study unaffected carriers of als/ftd-associated gene mutations to investigate the first steps in the disease process that leads to motor neuron degeneration, with the goal of identifying early disease targets and points of intervention to slow or stop disease onset and progression. unaffected individuals who have either a family member with a known als/ftd-associated gene mutation or have a strong family history of als and ftd are invited to participate in the als families project. for those who enroll, research visits will occur every 6-12 months.

Eligibility criteria:
inclusion criteria: * men or women of any race or ethnicity aged 18 or older * no symptoms of als or fronto-temporal dementia at enrollment * scenario 1: has already had genetic testing that identified an als-spectrum gene mutation. * scenario 2: has a first degree relative who was/is an obligate carrier of a familial als-spectrum gene mutation. * scenario 3: has a first degree relative who has/had an als-spectrum diagnosis who had a confirmed als-spectrum gene mutation or comes from a family with a high burden of als-spectrum diagnoses and a known als-spectrum gene mutation. * scenario 4: is deemed to be at high risk for carrying an als-spectrum gene mutation as judged by a review of the family structure and genetic information by the study team. * willing to undergo genetic analysis, with option of whether or not to learn results * willing to travel to columbia university irving medical center (cuimc) every 6-24 months for study procedures * capable of providing informed consent and following study procedures, or has a legally authorized representative who is able to consent for the subject. exclusion criteria for participation in biosample portion of the study: * known hiv * known hepatitis b * known hepatitis c

Keywords: pre-symptomatic familial fals genetic testing c9orf72 sod1 tardbp fus vcp pfn1
coagulation/complement activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis; Relapse

Summary: this is a multi-center, prospective, controlled study. ms patients (1° group: 30 patients in relapse; 2° group: 30 patients in remission) and age/sex-matched healthy controls (3° group: 30 subjects) will be enrolled in the study. patients' disability level will be evaluated by edss and msfc. patients and controls will be tested for either coagulation/complement (c3, c4, c4a, c9, fibrinogen, factor viii and x, d-dimer, protein c, protein s, antithrombin, factor ii, aptt, von-willebrand factor), soluble markers of endothelial damage (thrombomodulin, endothelial protein c receptor), antiphospholipid antibodies, lupus anticoagulant, complete blood count, viral serological assays or microrna microarray. patients will undergo dynamic susceptibility contrast-enhanced mri using a 3.0-t scanner to evaluate cbf, cbv, mtt, lesion number and volume.


Eligibility criteria:
inclusion criteria: * patients diagnosed with relapsing-remitting multiple sclerosis, untreated or treated with only immunomodulatory therapy, in relapse o in remission exclusion criteria: * pregnant, with any neoplastic, hematologic, thyroid, metabolic, thrombotic or autoimmune disease, drug or alcohol addicted, treated with immunosuppressive drugs, steroids o any medication interfering with coagulation.

Keywords: multiple sclerosis relapse coagulation complement cerebral blood flow
clinical trial to evaluate the efficacy and safety of uni-deb for unresectable hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma Non-resectable

Summary: pivotal clinical trial to evaluate the efficacy and safety of uni-deb for unresectable hepatocellular carcinoma


Eligibility criteria:
inclusion criteria: * over 19 years * diagnosis of hcc * unresectable asymtomatic uninodular or multinodular tumor. * subject who maintain clinically normal hepatopetal flow without main portal vein closure * at least one measurable target lesion by ct or mri which 10 mm or more and 100 mm or less. * ecog performance status of 0 or 1. * child-pugh class a or b * life expectancy of at least 6 months. exclusion criteria: * another primary tumour, with the exception of conventional basal cell carcinoma or superficial bladder neoplasia * hepatic resection, liver transplantation or percutaneous local treatment * previously received hcc related medical procedure * previously treated with anthracyclines * only measurable disease is within an area of the liver previously subjected to radiotherapy. * child pugh c * active gastrointestinal bleeding within 6 months from screening. * total bilirubin \> 3mg/dl * wbc \< 3,000cells/mm3 * platelet \< 50,000mm3 * serum creatinine \> 2mg/dl * inr\> 1.4 * alt and ast \> 5 times unl * diffuse hcc defined as \>50% tumour involvement of the whole liver.
examining feasibility and acceptability of telemedicine for substance use disorder (sud)

Conditions: Substance Use Disorders; Substance Use; Substance Dependence

Summary: the objective of this pilot intervention study is to iteratively refine motivational interviewing and psychosocial intervention programs delivered via telehealth (teletx) to help improve substance use and other related outcomes in sud patients who are not receiving sud care. we will examine feasibility and acceptability of these pilot psychosocial programs in a total of n=50 participants. the goal is to refine the programs to improve acceptability and feasibility and collect preliminary data for a future fully powered randomized controlled trial (rct) in the future. in addition to study sessions, participants that are enrolled in the study will complete surveys prior to, during, and after treatment.


Eligibility criteria:
inclusion criteria: * outpatient care at michigan medicine in past year * diagnostic and statistical manual of mental disorders (dsm-5) sud diagnosis and/or substance use on average of 2 days a week over the past month * have a smart phone, tablet or another wi-fi or data-enabled device (e.g. with a camera) exclusion criteria: * inability to speak or understand english * conditions that preclude informed consent (e.g., acute psychosis, cognitive deficits) or understanding of assessment or program content * prior alcohol withdrawal seizures or delirium tremens (dts). those who are at-risk of complicated withdrawal (e.g., seizures, dts) require greater medical attention and will be excluded and referred to their clinician for medical management.

Keywords: telehealth motivational interviewing cognitive behavioral therapy
clinical and radiographic assessment of nano-bioactive glass combined with i-prf scaffold in vital pulp treatments in mandibular molars with closed apices

Conditions: Vital Pulp Treatment in Mature Permanent Teeth With Irreversible Pulpitis

Summary: clinical, radiographic and pain assessment of vital pulp treatment in patients suffering from irreversible pulpitis in mature permanent molars. total pulpotomy is investigated using i-prf only vs i-prf mixed with nano-bioactive glass.


Eligibility criteria:
inclusion criteria: * patients suffering from symptomatic irreversible pulpitis in mature mandibular molars only will be involved. * tooth should give positive response to cold test * haemostasias should be achieved after total pulpotomy * the tooth is restorable and free from advanced periodontal disease, cracks and splits. * patients should be free from any systemic disease that may affect normal healing and predictable outcome. * patients who will agree to the consent and will commit to follow-up period. * patients with mature root apices * patients with no internal or external resorption and no periapical lesions * soft tissues around the tooth are normal with no swelling or sinus tract. exclusion criteria: * patients with immature roots. * haemostasias after 10 minutes can not be controlled after total pulpotomy * patients with any systemic disease that may affect normal healing. * patients with periapical lesions or infections. * pregnant females. * patients who could/would not participate in a 6 months follow-up. * patients with fistula or swelling * patients with necrotic pulp. * patients with old age.